Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in Photonics established ... annual meeting drew praise from community leaders from SPIE ... the action “a huge step forward … a lasting ... , The Board of Stakeholders voted to approve in ... its 29 April meeting in Brussels, which was sponsored ...
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)... BEIJING , May 17, 2013  Yongye International, ... "Company"), a leading developer, manufacturer, and distributor of crop ... China , today announced that, on May 16, ... board of directors (the "Board of Directors") was provided ... ( Hong Kong ) Limited ("Abax") to ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... Prescott, Wis. - The winding roads and hilly terrain ... Mississippi River suggest agriculture or tourism, not high ... to be a wrong turn reveals a surprising destination. , ... soaring eye-level over the bluffs, sits the Phillips Plastics ...
... Corp ., a non-profit development company that helps small businesses, ... technology businesses. , ,MDC said it has closed on loans ... off of Lucigen Corp. , and to BioSystem ... Contest. , ,C5-6 Technologies, which will develop enzymes used to ...
... a series of articles on developing start-up companies in the technology ... business entity. , , Madison, Wis. - ... as to the type of entity to use, you should have ... most people think of first. Income taxes depend upon the type ...
Cached Biology Technology:In western Wisconsin, the innovation economy is growing 2In western Wisconsin, the innovation economy is growing 3Early Stage: Step 6 - Taxes, taxes, taxes! 2Early Stage: Step 6 - Taxes, taxes, taxes! 3Early Stage: Step 6 - Taxes, taxes, taxes! 4
(Date:5/16/2013)... African-American adults living closer to a fast food restaurant ... who lived further away from fast food, according to ... Center, and this association was particularly strong among those ... published online in the American Journal of Public ... to a fast food restaurant, and among lower-income African-Americans, ...
(Date:5/16/2013)... May 16, 2013 The relationship between the ... has not been clear. Schizophrenia is commonly associated ... There are clues that reduced IQ may be ... example, reduced cognitive ability may precede the onset ... present in healthy relatives of people diagnosed with ...
(Date:5/16/2013)... outside the bone marrow in the liver, the ... now show that a specific type of immune cell ... Balanced hematopoiesis is essential for the function of the ... in the liver and the spleen. Later the process ... normally serves as the sole source of blood cells ...
Breaking Biology News(10 mins):Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Genetic risk for schizophrenia is connected to reduced IQ 2Herpes infections: Natural killer cells activate hematopoiesis 2
... The tendency toward obesity is directly related to the brain ... according to a new study. Researchers at Tufts University School ... a predisposition to obesity and defective dopamine signaling in the ... 2008 issue of The FASEB Journal . ...
... link between alcohol consumption and increased risk of perennial allergic ... adult women. The study, published in the July ... the risk increased 3% for every additional alcoholic drink per ... increase in risk of seasonal allergic rhinitis according to alcohol ...
... Consuming large quantities of fish loaded with omega-3 fatty acids ... to a study led by the University of Pittsburgh Graduate ... of the Journal of the American College of Cardiology ... study also found that third- and fourth-generation Japanese Americans had ...
Cached Biology News:Obesity predisposition traced to the brain's reward system 2Obesity predisposition traced to the brain's reward system 3Alcohol is associated with risk of perennial allergic rhinitis 2Eating fish may explain very low levels of heart disease in Japan 2
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
... to histochemically detect specific ... pH in cultured cells ... specific marker is only ... (not found in presenescent/quiescent/immortal ...
Recombinant Mouse LIGHT/TNFSF14...
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Biology Products: